BeyondSpring

BeyondSpring axes 35% of US staff after November drug rejection

BeyondSpring parts ways with 35% of its U.S. staff as the company reels from a November FDA rejection and awaits answers from China regulators.

Kyle LaHucik Jan 12, 2022 10:05am

BeyondSpring lurches down as FDA rejects plinabulin

Dec 3, 2021 7:45am

BeyondSpring, flying high from phase 3 success, inks cancer deal

Aug 27, 2021 8:20am

BeyondSpring lands on Nasdaq with $54M IPO

Mar 9, 2017 10:44am